Evotec Discontinues EVT 301 Development Programme: Financial News - Yahoo! Finance

Evotec Discontinues EVT 301 Development Programme: Financial News - Yahoo! Finance: "Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today reported that during the one month safety and tolerability study with EVT 301 in young and elderly volunteers, several cases of asymptomatic elevated liver function tests in the elderly group have been observed. All cases reversed spontaneously. No cases of elevated liver function tests were observed within the young healthy volunteer group."